Kindred Biosciences, Inc. (KIN): Price and Financial Metrics
KIN Stock Summary
- With a market capitalization of $181,070,052, Kindred Biosciences Inc has a greater market value than just 23.18% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at 1.4 for Kindred Biosciences Inc; that's greater than it is for only 20.05% of US stocks.
- As for revenue growth, note that KIN's revenue has grown 919.23% over the past 12 months; that beats the revenue growth of 98.99% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Kindred Biosciences Inc are CERS, VXRT, EPZM, GTHX, and TRVN.
- KIN's SEC filings can be seen here. And to visit Kindred Biosciences Inc's official web site, go to www.kindredbio.com.
KIN Stock Price Chart Interactive Chart >
KIN Price/Volume Stats
| Current price | $4.63 | 52-week high | $11.93 |
| Prev. close | $4.59 | 52-week low | $3.11 |
| Day low | $4.45 | Volume | 100,906 |
| Day high | $4.68 | Avg. volume | 477,586 |
| 50-day MA | $4.76 | Dividend yield | N/A |
| 200-day MA | $4.35 | Market Cap | 182.85M |
Kindred Biosciences, Inc. (KIN) Company Bio
Kindred Biosciences, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for pets. The companys product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company was founded in 2012 and is based in Burlingame, California.
Latest KIN News From Around the Web
Below are the latest news stories about Kindred Biosciences Inc that investors may wish to consider to help them evaluate KIN as an investment opportunity.
Kindred Biosciences Announces Two New Appointments to Board of DirectorsKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its Board of Directors, effective February 5, 2021. |
EFFECT - Kindred Biosciences, Inc. (0001561743) (Filer) - Stocks News FeedAccepted 2021-02-03 00:15:50 Documents Thank you for supporting Stocks News Feed. As an Amazon affiliate, we earn from qualifying purchases. 1 Effectiveness Date 2021-02-02 Registration Form S-3 Document Format Files Mailing Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 Business Address 1555 BAYSHORE HIGHWAY, SUITE 200 BURLINGAME CA 94010 650-701-7901 Kindred Biosciences, Inc. (Filer)… Read More »EFFECT – Kindred Biosciences, Inc. (0001561743) (Filer) |
These 2 Penny Stocks Could Rally All the Way to $11, Say AnalystsAt its January FOMC meeting, the Federal Reserve held interest rates steady – they are near rock-bottom now, and to no one’s surprise, the Fed is keeping them there. Fed Chairman Jerome Powell may have fed some market pessimism when he spoke after the meeting, and pointed out that unemployment, which has been rising in recent months. For market watchers seeking support, there is solace in the Fed’s monetary policy. The central bank is committed to buying $80 billion monthly in Treasury notes, and has put a rate increase on hold, likely until 2023. At least one top strategist sees the current market environment in terms of opportunity. |
Kindred Biosciences, Inc. (NASDAQ:KIN) Director Sells $195,345.00 in StockKindred Biosciences, Inc. (NASDAQ:KIN) Director Denise Bevers sold 39,069 shares of the firm’s stock in a transaction dated Thursday, January 7th. The stock was sold at an average price of $5.00, for a total value of $195,345.00. Following the transaction, the director now owns 143,835 shares in the company, valued at approximately $719,175. The sale […] |
Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study for Anti-TNFα Antibody for Canine Inflammatory Bowel DiseaseKindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced positive results from the pilot field effectiveness study of its monoclonal antibody against tumour necrosis factor alpha (anti-TNFα antibody) for canine inflammatory bowel disease (IBD). |
KIN Price Returns
| 1-mo | 0.87% |
| 3-mo | 18.72% |
| 6-mo | 10.50% |
| 1-year | -52.07% |
| 3-year | -45.85% |
| 5-year | 20.57% |
| YTD | 7.42% |
| 2020 | -49.17% |
| 2019 | -22.56% |
| 2018 | 15.87% |
| 2017 | 122.35% |
| 2016 | 25.00% |
Continue Researching KIN
Want to do more research on Kindred Biosciences Inc's stock and its price? Try the links below:Kindred Biosciences Inc (KIN) Stock Price | Nasdaq
Kindred Biosciences Inc (KIN) Stock Quote, History and News - Yahoo Finance
Kindred Biosciences Inc (KIN) Stock Price and Basic Information | MarketWatch
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...